medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2008, Number 05-06

<< Back Next >>

Medicina & Laboratorio 2008; 14 (05-06)

Lupus eritematoso sistémico

Gómez-Puerta JA, Cervera R

Language: Spanish
References: 52
Page: 211-223
PDF size: 2032.03 Kb.


ABSTRACT

Systemic lupus erythematosus (SLE) is the most diverse of the systemic autoimmune diseases and is characterized by the production of multiple autoantibodies, some of them closely related with specific disease features. SLE affects especially young female patients during childbearing ages. However, it can develop at any age. SLE pathogenesis remains unclear, however, several factors have been implicated, including genetic, environmental and hormonal. Additionally, cellular dysregulations (in B and T cells, apoptosis) and a cytokine imbalance have been described. Its clinical presentation is heterogeneous and any organ can be involved. The main clinical features include arthritis, cutaneous rash, glomerulonephritis, serositis (pleuritis and/or pericarditis), central nervous system involvement and in some occasions thrombosis. One of the main prognostic factors is renal involvement, which clearly reduces survival rates. Recent studies suggest a better control of the disease, reducing SLE flares and improving survival rates. During the past few years, several new treatments have been developed, some of them with promising results.


REFERENCES

  1. D’Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erytheatosus. Lancet 2007; 369: 587-596.

  2. Benseler SM, Silverman ED. Systemic lupus erythematosus. Rheum Dis Clin North Am 2007; 33: 471-498.

  3. Molina-Restrepo JF. El laboratorio en las enfermedades reumáticas autoinmunes. Medicina & Laboratorio 2007; 13: 11-33.

  4. Tripodi A. Laboratory testing for lupus anticoagulants: a review of issues affecting results. Clin Chem 2007; 53: 1629-1635.

  5. Tucker LB. Making the diagnosis of systemic lupus erythematosus in children and adolescents. Lupus 2007; 16: 546-549.

  6. Mosca M, Bombardieri S. Assessing remission in systemic lupus erythematosus. Clin Exp Rheumatol 2006; 24: S-99-104.

  7. Kurien BT, Scofield RH. Autoantibody determination in the diagnosis of systemic lupus erythematosus. Scand J Immunol 2006; 64: 227-235.

  8. Rouquette AM, Desgruelles C. Detection of antibodies to dsDNA: an overview of laboratory assays. Lupus 2006; 15: 403-407.

  9. Sinico RA, Bollini B, Sabadini E, Di Toma L, Radice A. The use of laboratory tests in diagnosis and monitoring of systemic lupus erythematosus. J Nephrol 2002; 15 Suppl 6: S20-27.

  10. Blotzer JW. Systemic lupus erythematosus I: historical aspects. Md State Med J 1983; 32: 439-441.

  11. Holubar K. Terminology and iconography of lupus erythematosus. A historical vignette. Am J Dermatopathol 1980; 2: 239-242.

  12. Smith CD, Cyr M. The history of lupus erythematosus. From Hippocrates to Osler. Rheum Dis Clin North Am 1988; 14: 1-14.

  13. Hebra F. On diseases of the skin including the exanthemata, Vol 1. Adams F (trans). Londres, The New Sydenham Society; 1866.

  14. Cazenave PLA, Schedel HE. Manual of the diseases of the skin. Burgess (trans). Londres, Henry Renshaw; 1852.

  15. Kaposi M. Lupus vulgaris. In Hebra F, Kaposi M (eds). On diseases of the skin including the exanthemata, Vol IV. Tay W (tran). Londres, The New Sydenham Society; 1875.

  16. Jadassohn J. Lupus erythematodes. In Mracek F (ed). Handbuch der Hautkrankheiten. Wein, Alfred Holder. 1904; 298-4041.

  17. Osler W. On the visceral complications of erythema exudativum multiforme. Am J Med Sci 1895; 110:629-646.

  18. Baeher G, Klemperer P, Schifrin A. A diffuse disease of the peripheral circulation usually associated with lupus erythematosus and endocarditis. Trans Assoc Am Physicians 1935; 50: 139-155.

  19. Klemperer P, Pollack AD, Baehr G. Pathology of disseminated lupus erythematosus. Arch Pathol 1941; 32: 569-631.

  20. Hargraves MM, Richmond H, Morton R. Presentation of two bone marrow elements: the “tart” cell and “L.E.” cell. Proc Staff Mtg Mayo Clinic 1948; 23: 25-28.

  21. Friou GJ. Antinuclear antibodies: diagnostic significance and methods. Arthritis Rheum 1967;10: 151-159.

  22. Stollar D, Levine L. Antibodies to denatured deoxyribonucleic acid in lupus erythematosus serum. V. Mechanism of inhibition by chloroquine Arch Biochem Biophys 1963; 101: 335-341.

  23. Krishnan C, Kaplan MH. Immunopathologic studies of systemic lupus erythematosus. II. Antinuclear reaction of gamma-globulin eluted from homogenates and isolated glomeruli of kidneys from patients with lupus nephritis. J Clin Invest 1967; 46: 569-579.

  24. Schur PH, Sandson J. Immunologic factors and clinical activity in systemic lupus erythematosus. N Engl J Med 1968; 278: 533-538.

  25. Holman HR. Partial purification and characterization of an extractible nuclear antigen which reacts with SLE sera. Ann N Y Acad Sci 1965; 124: 800-806.

  26. Sharp GC, Irvin WS, LaRoque RL, Velez C, Daly V, Kaiser AD, et al. Association of autoantibodies to different nuclear antigens with clinical patterns of rheumatic disease and responsiveness to therapy. J Clin Invest 1971; 50: 350-359.

  27. Farber SJ, Bole GG. Antibodies to components of extractable nuclear antigen. Clinical characteristics of patients. Arch Intern Med 1976; 136: 425-431.

  28. Tincani A, Meroni PL, Brucato A, Zanussi C, Allegri F, Mantelli P, et al. Anti-phospholipid and anti-mitochondrial type M5 antibodies in systemic lupus erythematosus. Clin Exp Rheumatol 1985; 3: 321-326.

  29. Font J, Cervera R, Bove A, Casals FJ. Antiphospholipid antibodies as markers of systemic lupus erythematosus. Med Clin (Barc) 1987; 89: 528.

  30. Iglesias-Gamarra A. Los primeros pasos. In Historia del lupus. Iglesias Gamarra A. Panamericana; Bogotá. 2003; 3-88.

  31. Cervera R, Abarca-Costalago M, Abramovicz D, Allegri F, Annunziata P, Aydintug AO, et al. Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the “Euro-Lupus Project”. Autoimmun Rev 2006; 5: 180-186.

  32. Duran S, Gonzalez LA, Alarcon GS. Damage, accelerated atherosclerosis, and mortality in patients with systemic lupus erythematosus: lessons from LUMINA, a multiethnic US cohort. J Clin Rheumatol 2007; 13: 350-353.

  33. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.

  34. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.

  35. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526-1533.

  36. Cervera R, Pallares L. Epidemiología y clasificación del lupus eritematoso sistémico. In Avances en lupus eritematoso sistémico. Cervera R, Jiménez- Alonso J. Marge Medica Books; Barcelona. 2008; 9-22.

  37. Alarcón-Segovia D, Alarcón-Riquelme ME. Etipoatogenia. Lupus eritematoso sistémico. In Tratado hispanoamericano de reumatología. Alarcón-Segovia D, Molina J, Molina JF, Catoggio L, Cardiel MH, Angulo JM. Editorial Normos S.A.; Bogotá, Colombia. 2006.

  38. Correa PA, Molina JF, Pinto LF, Arcos-Burgos M, Herrera M, Anaya JM. TAP1 and TAP2 polymorphisms analysis in northwestern Colombian patients with systemic lupus erythematosus. Ann Rheum Dis 2003; 62: 363-365.

  39. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003; 82: 299-308.

  40. Font J, Pallares L, Cervera R, Lopez-Soto A, Navarro M, Bosch X, et al. Systemic lupus erythematosus in the elderly: clinical and immunological characteristics. Ann Rheum Dis 1991; 50: 702-705.

  41. Gaviria LM, Rodelo JR, Uribe O, Vásquez G, Ramírez LA. Características clínicas y serológicas de los pacientes con LES de inicio tardío en una población colombiana. Rev Col Reumatol 2007;14: 23-31.

  42. Escobar MC, Gomez-Puerta JA, Albert D, Ferrer Q, Girona J. Recurrent congenital heart block in neonatal lupus. Clin Rheumatol 2007; 26: 1161-1163.

  43. Gómez-Puerta JA, Font J. Nefropatía lúpica. Actualización en su clasificación y tratamiento. Inmunológica 2006; 2: 5-13.

  44. Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15: 241-250.

  45. Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized rial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46: 2121-2131.

  46. Sinclair A, Appel G, Dooley MA, Ginzler E, Isenberg D, Jayne D, et al. Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Lupus 2007; 16: 972-980.

  47. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343: 1156-1162.

  48. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976; 60: 221-225.

  49. Font J, Cervera R. What to do to improve the survival of patients with systemic lupus erythematosus?. Med Clin (Barc) 2007; 128: 95-96.

  50. Gomez-Puerta JA, Cucho Venegas M, Cervera Segura R, Font Franco J. Intravenous immunoglobulins in the systemic autoinmune diseases. Rev Clin Esp 2003; 203: 548-554.

  51. Crispin JC, Kyttaris V, Juang YT, Tsokos GC. Systemic lupus erythematosus: new molecular targets. Ann Rheum Dis 2007; 66 Suppl 3:iii65-69.

  52. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, Portales-Perez D, Baranda L, Abud-Mendoza C, et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006; 8: R83.




2020     |     www.medigraphic.com